VF in the News

ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis

07/06/21 ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis SAN CARLOS, Calif., July 06, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA),…...

Read more

The American College of Rheumatology/Vasculitis Foundation Release Three New Guidelines for Treatment of Vasculitis

FOR IMMEDIATE RELEASE July 9, 2021 Media Contact Amanda Head (Corna) [email protected] 404-679-5330 The American College of Rheumatology/Vasculitis Foundation Release Three New Guidelines for Treatment of Vasculitis ATLANTA — The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of…...

Read more

VF Awards Research Grant to Pulmonary/Critical Care Medicine Physician at OSU

Lynn A. Fussner, MD, Assistant Professor at The Ohio State University (OSU), Division of Pulmonary, Critical Care, and Sleep Medicine, has been awarded a one-year grant from the Vasculitis Foundation (VF) for her study, “Role of Monocytes and Alpha-1 Antitrypsin in ANCA-Associated Vasculitis.” Dr. Fussner’s goal is to identify better…...

Read more

2021 V-RED Winners

Along with a first-place winner, there are two honorable mentions in the VF’s 2021 Recognizing Excellence in Diagnostics (V-RED) award program. Now in its eighth year, V-RED has grown into a powerful awareness campaign that recognizes medical providers worldwide for making a critical, early diagnosis of vasculitis. “Each year I…...

Read more